Hak-Myung Lee

发表

Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism

N. Watts, J. Bilezikian, D. Shoback, 2019, The Journal of clinical endocrinology and metabolism.

A multicenter, open-label extension study of velaglucerase alfa in Japanese patients with Gaucher disease: Results after a cumulative treatment period of 24months.

T. Hongo, K. Murayama, H. Ida, 2016, Blood cells, molecules & diseases.

Citrulline correlations in short bowel syndrome-intestinal failure by patient stratification: Analysis of 24 weeks of teduglutide treatment from a randomized controlled study.

D. Seidner, P. Jeppesen, S. Gabe, 2019, Clinical nutrition.

Factors Associated With Response to Teduglutide in Patients With Short-Bowel Syndrome and Intestinal Failure.

D. Seidner, P. Jeppesen, S. Gabe, 2017, Gastroenterology.

Safety and Efficacy of Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism Randomly Assigned to Receive Fixed 25-μg or 50-μg Daily Doses.

J. Bilezikian, B. Clarke, T. Vokes, 2017, Clinical therapeutics.

Teduglutide for the treatment of adults with intestinal failure associated with short bowel syndrome: pooled safety data from four clinical trials

K. Iyer, D. Seidner, S. Schneider, 2020, Therapeutic advances in gastroenterology.

Enteral Autonomy and Days Off Parenteral Support With Teduglutide Treatment for Short Bowel Syndrome in the STEPS Trials

D. Seidner, P. Jeppesen, S. Gabe, 2019, JPEN. Journal of parenteral and enteral nutrition.

Reduction of Parenteral Nutrition and Hydration Support and Safety With Long‐Term Teduglutide Treatment in Patients With Short Bowel Syndrome−Associated Intestinal Failure: STEPS‐3 Study

K. Iyer, T. Ziegler, D. Seidner, 2018, Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition.

Home infusion of intravenous velaglucerase alfa: Experience from pooled clinical studies in 104 patients with type 1 Gaucher disease.

J. Charrow, A. Mehta, T. Burrow, 2017, Molecular genetics and metabolism.

Safety and efficacy of glycopyrrolate oral solution for management of pathologic drooling in pediatric patients with cerebral palsy and other neurologic conditions

R. S. Zeller, P. Cavanaugh, J. Davidson, 2012, Therapeutics and clinical risk management.

Randomized Phase III evaluation of the efficacy and safety of a novel glycopyrrolate oral solution for the management of chronic severe drooling in children with cerebral palsy or other neurologic conditions

R. S. Zeller, P. Cavanaugh, J. Davidson, 2012, Therapeutics and clinical risk management.

Therapeutics and Clinical Risk Management

R. S. Zeller, P. Cavanaugh, J. Davidson, 2022 .

Subanalysis of Teduglutide Efficacy and Safety Data from Patients with Crohnʼs Disease and Ulcerative Colitis in the STEPS Study: 575

U. Pape, P. Jeppesen, A. Grimm, 2016 .

Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.

Laurie D. Smith, T. Hangartner, J. Charrow, 2016, Molecular genetics and metabolism.

Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study.

T. Hassanein, G. Aithal, P. Newsome, 2020, Journal of hepatology.

Colon polyps in patients with short bowel syndrome before and after teduglutide: Post hoc analysis of the STEPS study series.

A. Forbes, D. Armstrong, D. Seidner, 2020, Clinical nutrition.

Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.

Laurie D. Smith, T. Hangartner, J. Charrow, 2016, Molecular genetics and metabolism.